GMP

HYTN Completes Acquisition of Prism Scientific Labs, Enhancing Psychedelic Compound Manufacturing Capabilities

Retrieved on: 
Saturday, July 20, 2024

These technologies include specialized equipment designed to increase both the total yield and the tryptamine profile of mushrooms by enabling the production of larger and more potent biomass for psychedelic drug manufacturing.

Key Points: 
  • These technologies include specialized equipment designed to increase both the total yield and the tryptamine profile of mushrooms by enabling the production of larger and more potent biomass for psychedelic drug manufacturing.
  • In consideration for the Acquisition, HYTN has issued to the former shareholders of Prism, all of whom are at arm’s length to HYTN, an aggregate of 12,100,100 common shares (“Consideration Shares”).
  • The Consideration Shares have a deemed acquisition price of $0.195 and are subject to a hold period of four months.
  • This acquisition represents a key pillar in HYTN's long term strategic growth plan, allowing us to leverage Prism's exclusive licenses to enhance our research and development capabilities.

ACROBiosystems Launches GMP Brand Resilient Supply at ISSCR to Accelerate Cell and Gene Therapy Development

Retrieved on: 
Thursday, July 18, 2024

NEWARK, Del., July 18, 2024 /PRNewswire/ -- At the recent International Society for Stem Cell Research (ISSCR) Annual Meeting in Hamburg, ACROBiosystems announced its new GMP-centered brand, Resilient Supply, with the mission of accelerating the advancement of cell and gene therapy (CGT) development.

Key Points: 
  • NEWARK, Del., July 18, 2024 /PRNewswire/ -- At the recent International Society for Stem Cell Research (ISSCR) Annual Meeting in Hamburg, ACROBiosystems announced its new GMP-centered brand, Resilient Supply, with the mission of accelerating the advancement of cell and gene therapy (CGT) development.
  • Dr. Anil Kumar, CMC Head for the European division at ACROBiosystems, delivered a presentation titled "Streamlining Cell Therapy Manufacturing with ACROBiosystems," showcasing how Resilient Supply supports a more efficient CGT development process, encompassing pilot to clinic stages.
  • The ISSCR Annual Meeting, convening over 4,000 global experts in stem cell research and regenerative medicine from across the globe.
  • The essence of Resilient Supply is thoroughly embedded in the design and operational philosophy of ACROBiosystems' GMP facility.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Gritstone bio, Inc. (GRTS)

Retrieved on: 
Thursday, July 18, 2024

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • If you purchased or otherwise acquired Gritstone securities during the Class Period, you may move the Court no later than August 16, 2024 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Scorpius Holdings Successfully Executes First cGMP Microbial Batches at San Antonio Facility

Retrieved on: 
Thursday, July 18, 2024

DURHAM, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the successful execution of its first current Good Manufacturing Practice (cGMP) microbial batches at its San Antonio manufacturing facility.

Key Points: 
  • DURHAM, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the successful execution of its first current Good Manufacturing Practice (cGMP) microbial batches at its San Antonio manufacturing facility.
  • This achievement underscores Scorpius' ability to meet the stringent regulatory and client-driven standards essential for the contract manufacturing of microbial biologics.
  • Scorpius is poised to execute additional cGMP activities throughout the remainder of the year, reinforcing its commitment to advancing U.S.-based GMP manufacturing capabilities.
  • Jeff Wolf, CEO of Scorpius Holdings, remarked, "We are thrilled to have successfully completed our first cGMP microbial batches at the San Antonio facility.

Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates

Retrieved on: 
Thursday, July 18, 2024

PluriCDMO™, launched earlier this year, leverages Pluri’s 47,000 square foot good manufacturing practice (GMP) cell production facility to manufacture cell-based products for life science companies.

Key Points: 
  • PluriCDMO™, launched earlier this year, leverages Pluri’s 47,000 square foot good manufacturing practice (GMP) cell production facility to manufacture cell-based products for life science companies.
  • From initial clinical trial batches to mass scale commercial production, PluriCDMO™ is a long-term partner and service provider for the cell therapy production needs of the most innovative companies.
  • "Working with Pluri marks a pivotal milestone, enhancing Kadimastem's capacity to manufacture our products under GMP conditions,” stated Ronen Twito, Executive Chairman & President of Kadimastem.
  • “This collaboration is integral to our strategy as we prepare for clinical trials and expand into the U.S. market with our AstroRx® product candidate."

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NIKE, Roblox, Gritstone, and Rivian and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 18, 2024

NIKE announced that quarterly revenues declined 1% year-over-year and quarterly wholesale revenues declined 7% year-over-year.

Key Points: 
  • NIKE announced that quarterly revenues declined 1% year-over-year and quarterly wholesale revenues declined 7% year-over-year.
  • Three months later, on September 29, 2022, investors learned more when NIKE reported its first quarter fiscal year 2023 financial earnings after market close.
  • On this news, Rivian’s stock price fell $3.94 per share, or 25.6%, to close at $11.45 per share on February 22, 2024.
  • For more information on the Rivian class action go to: https://bespc.com/cases/RIVN

Avirmax CMC Successfully Delivers First GMP Lot of AAV Vector Product for Clinical Trial Use

Retrieved on: 
Wednesday, July 17, 2024

HAYWARD, Calif., July 17, 2024 /PRNewswire/ -- Avirmax CMC, a leader in the innovation and manufacture of adeno-associated virus (AAV) vector-mediated biotherapeutics, announces the successful delivery to its first client with Good Manufacturing Practice (GMP) lots of AAV vector product trial use.

Key Points: 
  • HAYWARD, Calif., July 17, 2024 /PRNewswire/ -- Avirmax CMC, a leader in the innovation and manufacture of adeno-associated virus (AAV) vector-mediated biotherapeutics, announces the successful delivery to its first client with Good Manufacturing Practice (GMP) lots of AAV vector product trial use.
  • The delivered vector product will play a crucial role in the upcoming clinical trial, aimed at treating ocular diseases.
  • The production process ensures that the vector products meet the highest standards of quality and safety required for clinical use.
  • The successful delivery of this GMP lot demonstrates Avirmax CMC's readiness to support clinical trials and contribute to the development of effective gene therapies.

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers

Retrieved on: 
Wednesday, July 17, 2024

Once considered medical waste, cord blood has emerged as a valuable raw material with immense therapeutic potential in cell therapies.

Key Points: 
  • Once considered medical waste, cord blood has emerged as a valuable raw material with immense therapeutic potential in cell therapies.
  • In recent years, researchers have made significant strides in harnessing the unique properties of cord blood derived cells for combating cancer and promoting healthy aging.
  • Traditionally, cord blood banks cryopreserve the CBUs with the purpose to use them for mainly blood disorders.
  • Amongst these are the invaluable immune γδ T Cells, a rare subset of white blood cells which may be expanded from the CBU.

BioProcess360 Partners launch dedicated Life Sciences investment fund to grow emerging bioprocessing tools and technologies

Retrieved on: 
Wednesday, July 17, 2024

DELRAY BEACH, Fla., July 17, 2024 (GLOBE NEWSWIRE) -- BioProcess360 Partners today announced the launch of a new investment fund to support businesses with the growth of emerging tools and technologies used in the bioprocessing of traditional mAbs and newer drug modalities.

Key Points: 
  • DELRAY BEACH, Fla., July 17, 2024 (GLOBE NEWSWIRE) -- BioProcess360 Partners today announced the launch of a new investment fund to support businesses with the growth of emerging tools and technologies used in the bioprocessing of traditional mAbs and newer drug modalities.
  • BioProcess360 Partners will support businesses through R&D and commercialization challenges by combining investment capital, support from industry experts and connections to the leading global biopharmaceutical companies.
  • Being a serial entrepreneur, I know exactly what it takes to be truly successful in this space” said Chris Major, Founding Partner, BioProcess360 Partners.
  • It’s where our expertise lies but it’s also why we’re different to other investment partners,” said Chris.

EQS-News: invIOs selects INV501 lead candidate to progress into IND-enabling studies in glioblastoma and melanoma

Retrieved on: 
Wednesday, July 17, 2024

Initially, the compound will be evaluated as a potential treatment for glioblastoma, an aggressive form of brain cancer, as well as for melanoma, a potentially deadly skin cancer.

Key Points: 
  • Initially, the compound will be evaluated as a potential treatment for glioblastoma, an aggressive form of brain cancer, as well as for melanoma, a potentially deadly skin cancer.
  • The INV501 family of compounds was identified as part of a phenotypic screen for substances that can activate T cells.
  • The INV501 clinical candidate compound was selected based on extensive medicinal chemistry and pharmacological testing.
  • Furthermore, INV501 candidate compound is capable of crossing the blood-brain barrier, making it a promising candidate for the treatment of brain tumors, including glioblastoma.